Ultragenyx pharmaceutical inc. (RARE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenues:
Total revenues

36,309

35,593

25,800

24,149

18,172

16,261

11,763

12,794

10,677

-

198

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of sales

-3,503

5,107

2,683

766

452

507

273

141

225

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

112,961

83,061

100,144

96,045

78,105

71,618

70,041

76,835

75,504

61,527

60,412

58,436

51,269

50,746

48,711

43,332

40,415

44,565

29,704

23,104

17,364

13,521

12,854

11,239

8,353

8,204

6,762

7,199

5,664

Selling, general and administrative

47,516

41,877

41,006

39,812

38,829

34,476

31,095

30,718

31,435

37,720

23,499

20,005

18,685

19,808

17,183

14,738

13,207

11,593

10,232

7,038

4,138

3,422

2,981

2,422

1,986

1,321

999

1,048

1,083

Total operating expenses

156,974

130,045

143,833

136,623

117,386

106,601

101,409

107,694

107,164

99,248

83,911

78,441

69,954

70,554

65,894

58,070

53,622

56,158

39,936

30,142

21,502

16,943

15,835

13,661

10,339

9,525

7,761

8,247

6,747

Loss from operations

-120,665

-94,452

-118,033

-112,474

-99,214

-90,340

-89,646

-94,900

-96,487

-96,834

-83,713

-78,441

-69,954

-70,549

-65,783

-58,053

-53,622

-56,158

-39,936

-30,142

-21,502

-16,943

-15,835

-13,661

-10,339

-9,525

-7,761

-8,247

-6,747

Interest income

2,919

2,770

3,319

4,063

3,086

2,627

2,730

2,448

1,737

724

1,117

1,151

1,082

912

922

971

984

918

673

456

273

195

171

149

93

59

68

63

26

Gain from sale of priority review vouchers

-

-

-

-

-

-40,300

40,300

40,300

130,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of investment in Arcturus equity securities

7,668

-

2,166

9,828

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

8,082

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net:
Other expense

-456

154

-153

-376

-412

13

-147

-496

-4,958

-1,838

3,373

4,413

582

-1,615

-46

159

-119

20

31

-101

-150

10

-185

-73

-3,384

-1,940

-735

-343

12

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

876

1,130

865

938

704

355

123

205

-14

76

-3,291

-2,543

-667

406

14

Loss before income taxes

-118,616

-91,244

-112,701

-98,959

-96,540

-87,700

-87,063

-52,626

30,292

-97,948

-79,223

-72,877

-68,290

-

-64,907

-56,923

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for income taxes

409

2,561

293

213

216

126

247

102

39

-

4

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-119,025

-93,805

-112,994

-99,172

-96,756

-87,826

-87,310

-52,728

30,253

-81,731

-79,227

-72,891

-68,290

-71,287

-64,907

-56,923

-52,757

-55,220

-39,232

-29,787

-21,379

-16,738

-15,849

-13,585

-13,630

-11,317

-8,428

-8,590

-6,735

Net income (loss) per share:
Basic

-

-

-

-

-

-

-

-

0.63

-

-

-

-1.63

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

0.62

-

-

-

-1.63

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing net income (loss) per share:
Basic

-

-

-

-

-

-

-

-

48,190

-

-

-

41,841

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

49,077

-

-

-

41,841

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,738

-15,849

-13,585

-18,438

-18,665

-12,590

-10,829

-8,205

Net loss per share, basic and diluted

-2.05

-1.62

-1.96

-1.72

-1.82

-

-1.74

-1.06

-

-

-1.87

-1.72

-

-1.76

-1.64

-1.46

-1.35

-1.47

-1.03

-0.83

-0.63

-0.45

-0.50

-0.45

-0.85

-5.23

-3.48

-3.32

-2.84

Shares used in computing net loss per share, basic and diluted

57,995

57,871

57,707

57,519

53,209

-

50,319

49,819

-

-

42,471

42,346

-

40,796

39,551

39,028

38,970

38,915

38,268

35,937

34,008

31,753

31,631

30,055

21,582

3,756

3,621

3,257

2,893

Collaboration and License
Total revenues

27,215

28,423

21,585

19,247

14,238

12,797

9,015

10,519

9,362

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product Sales
Total revenues

6,479

7,170

4,215

4,902

3,934

3,464

2,748

2,275

1,315

-

-

-

-

-

111

17

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash Collaboration Royalty Revenue
Total revenues

2,615

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-